NSCLC cell line and xenograft work indicated that metformin could enhance the activity of EGFR inhibitor Gefitinib [112] and suppress tumor growth after Gefitinib withdrawal [113] (Table 1). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.